Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 26.2 %

Brooklyn ImmunoTherapeutics stock opened at $0.40 on Friday. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The business’s 50 day simple moving average is $0.86 and its 200 day simple moving average is $1.45. The company has a market cap of $23.52 million, a price-to-earnings ratio of -0.18 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.